EIGHT INTERNATIONAL PTERIDINE SYMPOSIUM

第八届国际蝶啶研讨会

• 批准号: 3433901
• 负责人: V M WHITEHEAD
• 金额: $ 0.8万
• 依托单位: MCGILL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-06-01 至 1987-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3433901
• 关键词: drug metabolism; folate; methotrexate; pteridines; travel

Folic acid, methotrexate and biopterin are the most prominent representatives of the pteridine group of compounds in relation to medicine and patient care. Deficiency of folic acid is a world-wide nutritional problem, Methotrexate is the most widely used cytotoxic chemotherapeutic agent for treatment of cancer, leukemia and certain non-neoplastic conditions. Defects in tetrahydro biopterin metabolism are associated with hereditary treatable mental deficiency and other metabolic abnormalities. The International Pteridine Symposia held every 4 years since 1952 provide forums for scientific interchange between chemists, biologists and clinicians working with these compounds. The Eighth Symposium will be held in Montreal in 1986. Among areas of emphasis at the meeting will be: production new compounds which may be useful in cancer and in treating some types of mental deficiency, clarification of metabolic pathways to aid in targetting biological intervention, molecular biology and control of enzymes which regulate cellular metabolism, and identification abnormal products of pterins in cancer and other conditions.

最突出的是叶酸、甲氨蝶呤和生物蝶呤 与药物有关的蝶啶类化合物的代表 和病人护理。叶酸缺乏是一种世界性的营养性疾病 问题是，甲氨蝶呤是使用最广泛的细胞毒性化疗药物 治疗癌症、白血病和某些非肿瘤性疾病的药物 条件。四氢生物蝶呤代谢缺陷与 遗传性的可治疗的精神缺陷和其他代谢异常。 自1952年以来每4年举行一次的国际蝶类研讨会提供了 化学家、生物学家和 研究这些化合物的临床医生。第八次研讨会将召开 1986年在蒙特利尔。会议的重点包括： 生产可能对癌症和某些疾病治疗有用的新化合物 精神缺陷的类型，澄清代谢途径以帮助 靶向生物干预、分子生物学与防治 调节细胞代谢的酶和鉴定异常 在癌症和其他条件下的蝶呤产品。